logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Nintendo hasn't shown off its upcoming Next Generation console at E3, the major gameshow, on fears of others copying it, reports said quoting video game developer Shigeru Miyamoto. At an investors meeting in Japan, the gaming console maker however revealed that it continues to look into the possibility of developing a virtual reality headset, but affordable and comfortable one. Kellogg's is entering into restaurant business with the opening of a new cafe in New York City, exclusively for cereals that may cost around $8 per bowl, reports said. The cafe, to be known as Kellogg's NYC, will be launched officially on July 4 in the heart of Times Square. Small businesses, who want to use Twitter to connect with their customers, have a new helper. The online social networking service provider has launched a standalone application: Twitter Dashboard. The company said in blog post that the new service is launching into beta in the U.S. and is available online at dashboard.twitter.com or via the Dashboard app in the App Store.
comments powered by Disqus
Follow RTT